Deucravacitinib Induces Proteasomal Degradation of YAP1 in Human Glioblastoma Cells
Synlett · 22.05.2024
DOI: 10.1055/a-2331-6463 ↗Kurz gefasst
Fachartikel in der Zeitschrift Synlett, erschienen am 22.05.2024. Verfasst von Shaonan Wang und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Deucravacitinib is a selective allosteric inhibitor of tyrosine kinase 2 (TYK2) recently approved by the FDA for the treatment of plaque psoriasis. We discovered that this compound induces proteasomal degradation of YAP1, the downstream effector of the Hippo signaling pathway, in human glioblastoma (GBM) cells (U-87 MG). This degradation is independent of the canonical Hippo pathway, which offers clues to alternative mechanisms for YAP1 regulation.
Zitieren
APA
Wang, S., Sun, M., Su, Y., Xu, Z., Li, A., & He, W. (2024). Deucravacitinib Induces Proteasomal Degradation of YAP1 in Human Glioblastoma Cells. Synlett. https://doi.org/10.1055/a-2331-6463
Vancouver
Wang S, Sun M, Su Y, Xu Z, Li A, He W. Deucravacitinib Induces Proteasomal Degradation of YAP1 in Human Glioblastoma Cells. Synlett. 2024. doi:10.1055/a-2331-6463
BibTeX
@article{Wang2024,
author = {Wang, Shaonan and Sun, Min and Su, Yajuan and Xu, Zhou and Li, Ang and He, Weiwei},
title = {Deucravacitinib Induces Proteasomal Degradation of YAP1 in Human Glioblastoma Cells},
journal = {Synlett},
year = {2024},
doi = {10.1055/a-2331-6463}
}
EUVIMED